In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Daewoong Pharmaceutical Company Ltd.

http://www.daewoong.com/

Latest From Daewoong Pharmaceutical Company Ltd.

Korea Q4 Roundup: GC’s IVIG US Approval, SK Biopharm Turns Around

Aside from mixed earnings at major South Korean pharma firms, recent updates across the local industry have included the ongoing leadership dispute at Hanmi Group, the approval and reimbursement of Yuhan’s lazertinib as a first-line NSCLC therapy and the US approval of GC Biopharma’s immuno-globulin product.

South Korea Companies

Zydus MD On Pipeline-In-A-Drug Approach, Partnering Intent

Zydus MD Sharvil Patel talks to Scrip about a pipeline-in-a-drug approach for novel molecules like ZYIL-1, the intent behind deals with Daewoong and LiqMeds and expected timelines for trial readouts of its PBC/NASH candidate saroglitazar

Commercial Clinical Trials

AI/ML Efforts, Quick Approvals, Regulator Digitalization: What India Is Doing For Drug Discovery

AI initiatives in a country known for its software prowess, along with startup support, clinical trial rule changes, crunched approval timelines, unified digital regulatory interfaces and a R&D policy laying out $600m in funds, are all meant to build something greater than the sum of its parts. In a bottom-up approach, India is building an innovation ecosystem

Research & Development Policy

Korea 2023 Review: R&D Potential Shines Through Despite Challenges

Despite some disappointments, the South Korean pharma industry showed mostly resilient R&D activity in 2023 amid robust efforts to secure technologies and assets in new modalities such as ADCs and TPD to better compete with global players. 

South Korea Companies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
UsernamePublicRestriction

Register